Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00099684
First received: December 17, 2004
Last updated: October 26, 2012
Last verified: October 2012
  Purpose

Anti-HIV drugs, especially protease inhibitors (PIs), have been linked to lipid metabolism problems, including elevations in low density lipoprotein cholesterol (LDL-c), triglycerides, and total cholesterol. Ezetimibe is a lipid-controlling drug; statins are part of another class of lipid-lowering drugs popularly prescribed to people with high cholesterol. The purpose of this study is to determine the safety, effectiveness, and tolerability of ezetimibe in combination with statin therapy in adults who are taking anti-HIV drugs and have high cholesterol.

Study hypothesis: In HIV infected adults, ezetimibe in combination with statin therapy will result in significantly lower LDL-c compared to statin therapy alone.


Condition Intervention
HIV Infections
Drug: Ezetimibe

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Pilot Study of the Safety, Efficacy, and Tolerability of Ezetimibe (Zetia) in Combination With Statin Therapy for the Treatment of Elevated LDL Cholesterol in HIV-Infected Subjects

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Change in directly measured fasting LDL-c while receiving ezetimibe compared to change while receiving placebo
  • changes in clinical symptoms and safety labs while receiving ezetimibe compared to changes in clinical symptoms while receiving placebo

Enrollment: 44
Study Start Date: November 2005
Study Completion Date: May 2007
Detailed Description:

Lipid metabolism abnormalities are common complications of HIV therapy, particularly with PIs. Statins and other lipid-lowering agents are often prescribed to control elevated cholesterol levels in both HIV infected and uninfected people. However, both antiretroviral therapy (ART) and lipid-lowering drugs may be associated with cardiovascular disease, so there is a clear need to find a lipid-lowering drug with low toxicity. This study will evaluate the safety, efficacy, and tolerability of ezetimibe, a lipid-controlling agent, in combination with ongoing statin therapy in HIV infected people currently on ART.

This study will last 28 weeks. All participants will be required to continue their current stable statin therapy and ART for the duration of the study.

Participants will be randomly assigned to one of two arms. Arm 1 participants will receive ezetimibe daily for 12 weeks, no treatment for 4 weeks, then placebo daily for 12 weeks. Arm 2 participants will receive placebo daily for 12 weeks, no treatment for 4 weeks, and then ezetimibe daily for 12 weeks. There will be 9 study visits; they will occur at study screening, at study entry, and every 4 weeks thereafter. Clinical assessment and blood collection will occur at all visits. Participants will be asked to complete an adherence questionnaire at Weeks 4, 12, 20, and 28, and will also be encouraged to coenroll in ACTG A5128 (Consent for Use of Stored Patient Specimens for Future Testing).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV infected
  • On ART for at least 3 months prior to study entry, and on stable ART for at least 30 days prior to study entry
  • Taking one of the study-recommended statins for at least 3 months prior to study entry, and on stable statin therapy for at least 30 days immediately prior to study entry
  • On lipid-lowering diet and exercise program for at least 30 days prior to screening, and willing to continue both for the duration of the study
  • LDL-c of 130 mg/dL or greater within 30 days prior to study entry
  • Willing to use acceptable forms of contraception
  • If on hormone replacement therapy, must be on a stable dose or dose-equivalent therapy for at least 30 days prior to study entry, and must be willing to continue the same dose for the duration of the study. People taking physiologic testosterone replacement therapy are not excluded.
  • If taking oral contraceptives, must be on a stable dose or dose-equivalent therapy for at least 30 days prior to study entry, and must be willing to continue the same dose for the duration of the study

Exclusion Criteria:

  • Active cancer or new diagnosis of cancer within the last 5 years. People with skin cancers, including Kaposi's sarcoma, that do not require systemic treatment are not excluded.
  • Prior use of ezetimibe
  • Known allergy or sensitivity to ezetimibe or its components
  • Diabetes mellitus or use of any diabetic medications within 30 days prior to study entry
  • History of coronary heart disease
  • History of or current congestive heart failure (New York Heart Association Class III or IV)
  • Known atherosclerotic disease risk (e.g., history of myocardial infection, bypass surgery, angioplasty, angina pectoris with a positive stress test or angiographic documentation)
  • Vascular abnormalities (e.g., cerebrovascular disease, peripheral vascular disease, abdominal aortic aneurysm, or leg artery blockages)
  • Untreated or uncontrolled hypothyroidism
  • Current drug or alcohol abuse that may interfere with the study
  • Testosterone therapy beyond normal physiologic levels of the hormone within 3 months prior to study entry
  • Initiation or change in physiologic testosterone replacement therapy within 3 months prior to study entry
  • Hormonal anabolic therapies within 3 months prior to study entry
  • Systemic cancer chemotherapy or immunomodulators (e.g., growth factors, immune globulin, interleukins, and interferons) within 60 days prior to study entry
  • Lipid-lowering agents (except statins) within 30 days prior to study entry
  • Any corticosteroid therapy above replacement levels within 30 days prior to study entry
  • Untreated or uncontrolled hypertension
  • Active AIDS-defining opportunistic infection (OI) within 30 days prior to study entry. People who have no evidence of active disease and are receiving maintenance therapy for AIDS-related OIs are not excluded.
  • Acute illness that would interfere with the study within 30 days prior to study entry
  • Investigational agents. People using expanded access investigational antiretroviral drugs are not excluded.
  • Decreased mental capacity that may interfere with the study
  • Pregnant or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00099684

  Hide Study Locations
Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35924-2050
United States, California
University of Southern California
Los Angeles, California, United States, 90033-1079
UCLA School of Medicine
Los Angeles, California, United States, 77555-0435
University of California, San Diego Antiviral Research Center
San Diego, California, United States, 92103
San Francisco General Hospital
San Francisco, California, United States, 94110
Santa Clara Valley Medical Center
Stanford, California, United States, 94305-5107
San Mateo County AIDS Program
Stanford, California, United States, 94305-5107
Willow Clinic
Stanford, California, United States, 94305-5107
Stanford University
Stanford, California, United States, 94305-5107
United States, District of Columbia
Georgetown University Medical Center
Washington, District of Columbia, United States, 20007
United States, Florida
University of Miami
Miami, Florida, United States, 33136-1013
United States, Hawaii
University of Hawaii
Honolulu, Hawaii, United States, 96816-2396
United States, Illinois
Rush-Presbyterian/St. Lukes (Chicago)
Chicago, Illinois, United States, 60611-3015
Cook County Hospital Core Center
Chicago, Illinois, United States, 60612
Feinberg School of Medicine, HIV/ACTU
Chicago, 60611-3015, Illinois, United States, 60611-3015
United States, Indiana
Indiana University Hospital
Indianapolis, Indiana, United States, 46202-5250
Wishard Hospital
Indianapolis, Indiana, United States, 46202
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455-0392
United States, Nebraska
Nebraska Health System
Omaha, Nebraska, United States, 68198-5130
United States, New York
SUNY - Buffalo (Rochester)
Buffalo, New York, United States, 14215
NYU/Bellevue
New York, New York, United States, 10016-6481
Chelsea Clinic
New York, New York, United States, 10011
Beth Israel Medical Center
New York, New York, United States, 10003
The Cornell Clinical Trials Unit
New York, New York, United States, 10021
Columbia University
New York, New York, United States, 10032-3784
Community Health Network, Inc.
Rochester, New York, United States, 14642-0001
University of Rochester Medical Center
Rochester, New York, United States, 14642-0001
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267-0405
MetroHealth Medical Center
Cleveland, Ohio, United States, 44109-1998
Ohio State University
Columbus, Ohio, United States, 43210
United States, Pennsylvania
Presbyterian Medical Center - Univ. of PA
Philadelphia, Pennsylvania, United States, 19104
University of Pennsylvania, Philadelphia
Philadelphia, Pennsylvania, United States, 19104
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213-2582
United States, Rhode Island
The Miriam Hospital
Providence, Rhode Island, United States, 02906
Rhode Island Hospital
Providence, Rhode Island, United States, 02906
Stanley Street Treatment and Resource
Providence, Rhode Island, United States, 02906
United States, Tennessee
Comprehensive Care Clinic
Nashville, Tennessee, United States, 37203
United States, Texas
Dallas VA Medical Center
Dallas, Texas, United States, 75235-9173
University of Texas, Galveston
Galveston, Texas, United States, 77555-0435
United States, Washington
University of Washington (Seattle)
Seattle, Washington, United States, 98104
Puerto Rico
University of Puerto Rico
San Juan, Puerto Rico, 00936-5067
Sponsors and Collaborators
Investigators
Study Chair: Susan Koletar, MD Division of Infectious Diseases, Ohio State University
Study Chair: Dominic Chow, MD, MPH University of Hawaii, Hawaii AIDS Clinical Research Program, Leahi Hospital
  More Information

Additional Information:
Publications:
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00099684     History of Changes
Other Study ID Numbers: ACTG A5209
Study First Received: December 17, 2004
Last Updated: October 26, 2012
Health Authority: United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Treatment Experienced

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Ezetimibe
Anticholesteremic Agents
Antimetabolites
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 20, 2014